Rahul Kodgule
Overview
Explore the profile of Rahul Kodgule including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
188
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kodgule R, Magar P, Shivnitwar S, Wu W, Pendse A, Creado S, et al.
Cureus
. 2025 Jan;
16(12):e75836.
PMID: 39822435
Background Cough in common cold is often associated with rhinorrhoea and nasal congestion, requiring treatment with a cough suppressant, decongestant, and antihistamine. Bilastine is a non-sedating antihistamine, a preferred option...
2.
Joshi S, Tandon M, Kodgule R, Wu W, Jadhao V, Suryawanshi S, et al.
J Assoc Physicians India
. 2024 May;
72(1):32-42.
PMID: 38736072
Background: The efficacy and safety of lobeglitazone sulfate has been reported only in the Korean population, and no study has been conducted in India. Materials And Methods: In this 16-week...
3.
Salvi S, Jain M, Krishnamurthy S, Balki A, Kodgule R, Tandon M, et al.
Lung India
. 2023 Jan;
39(6):517-524.
PMID: 36629230
Background: The safety and efficacy of fixed-dose combination (FDC) of glycopyrronium bromide 12.5 μg/formoterol fumarate 12 μg (GB/FF) twice daily as dry powder inhalers (DPIs) compared to glycopyrronium 50 μg...
4.
Tandon M, Wu W, Moore K, Winchester S, Tu Y, Miller C, et al.
Lancet Reg Health Southeast Asia
. 2022 Nov;
7:100110.
PMID: 36373109
[This corrects the article DOI: 10.1016/j.lansea.2022.100036.].
5.
Tandon M, Wu W, Moore K, Winchester S, Tu Y, Miller C, et al.
Lancet Reg Health Southeast Asia
. 2022 Jul;
3:100036.
PMID: 35784831
Background: Additional outpatient therapies which are readily accessible will be essential to reduce COVID-19 illness progression in high risk individuals. Especially as the virus continues to mutate with greater transmissibility...
6.
Salvi S, Balki A, Krishnamurthy S, Panchal S, Patil S, Kodgule R, et al.
ERJ Open Res
. 2021 Jul;
7(3).
PMID: 34322547
Background: The aim of this work was to investigate the safety and efficacy of single-inhaler triple therapy with 12.5 μg glycopyrronium (GB)/12 μg formoterol fumarate (FF)/250 μg fluticasone propionate (FP),...
7.
Salvi S, Deb A, Agarwal M, Tummuru V, Kodgule R, Hemalatha V, et al.
Pulm Pharmacol Ther
. 2020 Aug;
63:101932.
PMID: 32777289
Background: The use of triple therapy with inhaled corticosteroids, long-acting beta-agonist and long-acting antimuscarinics has been shown to be beneficial in COPD patients who continue to have symptoms and exacerbations,...
8.
Dharmalingam M, Aravind S, Thacker H, Paramesh S, Mohan B, Chawla M, et al.
Drugs
. 2020 Mar;
80(6):587-600.
PMID: 32162274
Background: Metformin is the first-line treatment for type 2 diabetes mellitus (T2DM), but many patients either cannot tolerate it or cannot achieve glycemic control with metformin alone, so treatment with...
9.
Lopresti A, Smith S, Malvi H, Kodgule R
Medicine (Baltimore)
. 2019 Sep;
98(37):e17186.
PMID: 31517876
Background: Ashwagandha (Withania somnifera (L.) Dunal) is a herb traditionally used to reduce stress and enhance wellbeing. The aim of this study was to investigate its anxiolytic effects on adults...
10.
Infante C, Chamberlain D, Kodgule R, Fletcher R
Annu Int Conf IEEE Eng Med Biol Soc
. 2017 Oct;
2017:1413-1416.
PMID: 29060142
Pulmonary and respiratory diseases (e.g. asthma, COPD, allergies, pneumonia, tuberculosis, etc.) represent a large proportion of the global disease burden, mortality, and disability. In this context of creating automated diagnostic...